SEARCH

SEARCH BY CITATION

References

  • 1
    Conter V,Aricò M,Basso G, et al. Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia. Leukemia 2010; 24: 255264.
  • 2
    Möricke A,Zimmermann M,Reiter A, et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981–2000. Leukemia 2010; 24: 265284.
  • 3
    Gaynon PS,Angiolillo AL,Carroll WL, et al. Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983–2002: A Children's Oncology Group report. Leukemia 2010; 24: 285297.
  • 4
    Silverman LB,Stevenson KE,O'Brien JE, et al. Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblasticleukemia (1985–2000). Leukemia 2010; 24: 320334.
  • 5
    Schmiegelow K,Forestier E,Hellebostad M, et al. Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia 2010; 24: 345354.
  • 6
    Pui CH,Campana D,Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 2009; 360: 27302741.
  • 7
    Mitchell C,Richards S,Harrison CJ, et al. Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukaemia, 1980–2001. Leukemia 2010; 24: 406418.
  • 8
    Pui CH,Robison LL,Look AT. Acute lymphoblastic leukaemia. Lancet 2008; 371: 10301043.
  • 9
    Chessells JM,Veys P,Kempski H, et al. Long-term follow-up of relapsed childhood acute lymphoblastic leukaemia. Br J Haematol 2003; 123: 396405.
  • 10
    Pallisgaard N,Hokland P,Riishøj DC, et al. Multiplex reverse transcription-polymerase chain reaction for simultaneous screening of 29 translocations and chromosomal aberrations in acute leukemia. Blood 1998; 92: 574588.
  • 11
    Pui CH,Relling MV,Downing JR. Acute lymphoblastic leukemia. N Engl J Med 2004; 350: 15351548.
  • 12
    Burmeister T,Gökbuget N,Schwartz S, et al. Clinical features and prognostic implications of TCF3-PBX1 and ETV6-RUNX1 in adult acute lymphoblastic leukemia. Haematologica 2010; 95: 241246.
  • 13
    Aricò M,Valsecchi MG,Camitta B, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000; 342: 9981006.
  • 14
    Pieters R. Infant acute lymphoblastic leukemia: Lessons learned and future directions. Curr Hematol Malig Rep 2009; 4: 167174.
  • 15
    Willman CL. Flow cytometric analysis of hematologic specimen. Neoplastic hematology. Baltimore: Williams & Wilkins; 1992. pp 169195.
  • 16
    ISCN. An International System for Human Cytogenetic Nomenclature. In: Mitelman F, editor. Basel, Switzerland: S Karger; 2005.
  • 17
    van Dongen JJ,Langerak AW,Brüggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98–3936. Leukemia 2003; 17: 22572317.
  • 18
    Cui L,Li Z,Wu M, et al. Combined analysis of minimal residual disease at two time points and its value for risk stratification in childhood B-lineage acute lymphoblastic leukemia. Leuk Res 2010; 34: 13141319.
  • 19
    Verhagen OJ,Willemse MJ,Breunis WB, et al. Application of germline IGH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia. Leukemia 2000; 14: 14261435.
  • 20
    van der Velden VH,Willemse MJ,van der Schoot CE, et al. Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR. Leukemia 2002; 16: 928936.
  • 21
    van der Velden VH,de Bie M,van Wering ER, et al. Immunoglobulin light chain gene rearrangements in precursor-B-acute lymphoblastic leukemia: Characteristics and applicability for the detection of minimal residual disease. Haematologica 2006; 91: 679682.
  • 22
    Brüggemann M,van der Velden VH,Raff T, et al. Rearranged T-cell receptor beta genes represent powerful targets for quantification of minimal residual disease in childhood and adult T-cell acute lymphoblastic leukemia. Leukemia 2004; 18: 709719.
  • 23
    Langerak AW,Wolvers-Tettero IL,van Gastel-Mol EJ, et al. Basic helix-loop-helix proteins E2A and HEB induce immature T-cell receptor rearrangements in nonlymphoid cells. Blood 2001; 98: 24562465.
  • 24
    Szczepanski T,van der Velden VHJ,van Dongen JJM. Real-time quantitative (RQ)-PCR for the detection of minimal residual disease in childhood acute lymphoblastic leukemia. Haematologica 2002; 87: 183191.
  • 25
    van der Velden VH,Wijkhuijs JM,Jacobs DC, et al. T cell receptor gamma gene rearrangements as targets for detection of minimal residual disease in acute lymphoblastic leukemia by real-time quantitative PCR analysis. Leukemia 2002; 16: 13721380.
  • 26
    Chen X,Pan Q,Stow P, et al. Quantification of minimal residual disease in T-lineage acute lymphoblastic with the TAL-1 deletion using a standardized real-time PCR assay. Leukemia 2001; 15: 166170.
  • 27
    van der Velden VH,Cazzaniga G,Schrauder A, et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: Guidelines for interpretation of real-time quantitative PCR data. Leukemia 2007; 21: 604611.
  • 28
    Nguyen K,Devidas M,Cheng SC, et al. Factors influencing survival after relapse from acute lymphoblastic leukemia: A Children's Oncology Group study. Leukemia 2008; 22: 21422150.
  • 29
    Borowitz MJ,Devidas M,Hunger SP, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: A Children's Oncology Group study. Blood 2008; 111: 54775485.
  • 30
    Usvasalo A,Räty R,Knuutila S, et al. Acute lymphoblastic leukemia in adolescents and young adults in Finland. Haematologica 2008; 93: 11611168.
  • 31
    Nachman JB,Heerema NA,Sather H, et al. Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood 2007; 110: 11121115.
  • 32
    Tsuchida M,Ohara A,Manabe A, et al. Long-term results of Tokyo Children's Cancer Study Group trials for childhood acute lymphoblastic leukemia, 1984–1999. Leukemia 2010; 24: 383396.
  • 33
    Liang DC,Yang CP,Lin DT, et al. Long-term results of Taiwan Pediatric Oncology Group studies 1997 and 2002 for childhood acute lymphoblastic leukemia. Leukemia 2010; 24: 397405.
  • 34
    Schlieben S,Borkhardt A,Reinisch I, et al. Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05–92. Leukemia 1996; 10: 957963.
  • 35
    Beyermann B,Agthe AG,Adams HP, et al. Clinical features and outcome of children with first marrow relapse of acute lymphoblastic leukemia expressing BCR-ABL fusion transcripts. BFM Relapse Study Group. Blood 1996; 87: 15321538.
  • 36
    Pui CH,Gaynon PS,Boyett JM, et al. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet 2002; 359: 19091915.
  • 37
    Moorman AV,Ensor HM,Richards SM, et al. Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: Results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncol 2010; 11: 429438.
  • 38
    Schultz KR,Pullen DJ,Sather HN, et al. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: A combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood 2007; 109: 926935.
  • 39
    Stow P,Key L,Chen X, et al. Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. Blood 2010; 115: 46574663.
  • 40
    Conter V,Bartram CR,Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: Results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010; 115: 32063214.
  • 41
    Liu JY,Li ZG,Gao C, et al. Characteristics of T cell receptor beta gene rearrangements and its role in minimal residual disease detection in childhood T-cell acute lymphoblastic leukemia. Zhonghua Er Ke Za Zhi 2008; 46: 487492.
  • 42
    Metzler M,Mann G,Monschein U, et al. Minimal residual disease analysis in children with t(12;21)-positive acute lymphoblastic leukemia: Comparison of Ig/TCR rearrangements and the genomic fusion gene. Haematologica 2006; 91: 683686.
  • 43
    Attarbaschi A,Mann G,Dworzak M, et al. Treatment results of childhood acute lymphoblastic leukemia in Austria-a report of 20 years' experience. Wien Klin Wochenschr 2002; 114: 148157.
  • 44
    Kager L,Lion T,Attarbaschi A, et al. Incidence and outcome of TCF3-PBX1-positive acute lymphoblastic leukemia in Austrian children. Haematologica 2007; 92: 15611564.
  • 45
    Bhojwani D,Pei D,Sandlund JT, et al. ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: Improved outcome with contemporary therapy. Leukemia 2012; 26: 265270.
  • 46
    Kager L,Cheok M,Yang W, et al. Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. J Clin Invest 2005; 115: 110117.
  • 47
    Schultz KR,Bowman WP,Aledo A, et al. Improved early event free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukaemia: A Children's Oncology Group study. J Clin Oncol 2009; 27: 51755181.